Global News Wire: Novavax Initiating Human Clinical Trials for H7N9 Virus

vaccineNovavax, Inc (NVAX) is a clinical-stage biopharmaceutical company that strives to create novel vaccines to treat a broad spectrum of diseases around the world. They have most recently announced the initiation of their Phase 1 clinical trial of a monovalent virus-like particle (VLP) potential vaccine to prevent the H7N9 virus.

Novavax has been progressing extremely rapidly and within three months have gone from multiple animal studies to initiating human clinical trials. Keep an eye for Novavax as they continue to power through their pipeline. Market Cap: $394.66million; Volume: 81,572; 12 Month Trail: $1.52-$2.77.

View the full article here: (

View the profile page here: (

The comments are closed.